Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 13/20 | 0.97 |
| ▸ | DRD3 known ✓ | P35462 | 10/20 | 0.97 |
| ▸ | DRD4 known ✓ | P21917 | 5/20 | 0.97 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.57 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.60 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7450582 | 1.00 | DRD2 (0.97) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL30335264 | 1.00 | DRD2 (0.97) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL29067180 | 1.00 | DRD2 (0.97) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL30485906 | 1.00 | DRD2 (0.97) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL29802351 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL12072682 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL1938120 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL7454456 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL604798 | 0.99 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B | |
| SCHEMBL15375766 | 0.91 | DRD2 (1.00) | DRD2DRD3DRD4MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111393309-B | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2023-03-31 | — | — | CN | claimed |
| CN-111393309-A | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| EP-2585428-B1 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-05-10 | — | — | EP | claimed |
| US-8981121-B2 | Process for the preparation of nitrogen substituted aminotetralins derivatives | UCB PHARMA GMBH (DE) | 2015-03-17 | — | — | US | claimed |
| EP-2585428-A2 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB Pharma GmbH (DE) | 2013-05-01 | — | — | EP | claimed |
| US-20130102794-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | UCB PHARMA GMBH (DE) | 2013-04-25 | — | — | US | claimed |
| WO-2011161255-A2 | NOVEL PROCESS FOR THE PREPARATION OF NITROGEN SUBSTITUTED AMINOTETRALINS DERIVATIVES | UCB PHARMA GMBH (DE) | 2011-12-29 | — | — | WO | claimed |
| CN-114805095-B | Preparation method of (S) -5-methoxy-1, 2,3, 4-tetrahydro-N-propyl-2-naphthylamine | 上海柏狮生物科技有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-111393309-B | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-111393309-B | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-111393309-B | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2023-03-31 | — | — | CN | disclosed |
| CN-111393309-A | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| CN-111393309-A | Preparation method of (S) -1,2,3, 4-tetrahydro-5-methoxy-N-propyl-2-naphthylamine hydrochloride | 上海皓元医药股份有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-10611749-B2 | Process for preparation of Rotigotine and intermediates thereof | SOLARA ACTIVE PHARMA SCIENCES LIMITED (IN) | 2020-04-07 | — | — | US | disclosed |
| US-20190248758-A1 | Novel Process for Preparation of Rotigotine and Intermediates Thereof | SOLARA ACTIVE PHARMA SCIENCES LIMITED (IN) | 2019-08-15 | — | — | US | disclosed |
| EP-2585428-B1 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-05-10 | — | — | EP | disclosed |
| US-8981121-B2 | Process for the preparation of nitrogen substituted aminotetralins derivatives | UCB PHARMA GMBH (DE) | 2015-03-17 | — | — | US | disclosed |
| EP-2585428-A2 | PROCESSES FOR THE RESOLUTION OF NITROGEN SUBSTITUTED (S)-5-ALKOXY-2-AMINOTETRALIN DERIVATIVES | UCB Pharma GmbH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102794-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | UCB PHARMA GMBH (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2011161255-A2 | NOVEL PROCESS FOR THE PREPARATION OF NITROGEN SUBSTITUTED AMINOTETRALINS DERIVATIVES | UCB PHARMA GMBH (DE) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248758-A1 | Novel Process for Preparation of Rotigotine and Intermediates Thereof | OAT, CYP11B1, MAOB | DRD2 217/4885DRD3 401/4885DRD4 129/4885 |
| US-10611749-B2 | Process for preparation of Rotigotine and intermediates thereof | OAT, CYP11B1, SRM | DRD2 375/4885DRD3 566/4885DRD4 161/4885 |
| US-20130102794-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | AANAT, AADAT, ASNS | DRD2 168/4885DRD3 329/4885DRD4 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.